Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity

Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OX...

Descripción completa

Detalles Bibliográficos
Autores: Velasco, Roser, Alemany, Montse, Villagrán, Macarena, Argyriou, Andreas A.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/179821
Acceso en línea:https://hdl.handle.net/2445/179821
Access Level:acceso abierto
Palabra clave:Marcadors bioquímics
Neurotoxicologia
Càncer gastrointestinal
Biochemical markers
Neurotoxicology
Gastrointestinal cancer
id ES_4067e1ae123b579e5e1df16b8a6325c8
oai_identifier_str oai:diposit.ub.edu:2445/179821
network_acronym_str ES
network_name_str España
repository_id_str
spelling Predictive Biomarkers of Oxaliplatin-Induced Peripheral NeurotoxicityVelasco, RoserAlemany, MontseVillagrán, MacarenaArgyriou, Andreas A.Marcadors bioquímicsNeurotoxicologiaCàncer gastrointestinalBiochemical markersNeurotoxicologyGastrointestinal cancerOxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OXA infusion, and chronic non-length dependent sensory neuronopathy symmetrically affecting both upper and lower limbs in a stocking-and-glove distribution. No effective strategy has been established to reverse or treat OXAIPN. Thus, it is necessary to early predict the occurrence of OXAIPN during treatment and possibly modify the OXA-based regimen in patients at high risk as an early diagnosis and intervention may slow down neuropathy progression. However, identifying which patients are more likely to develop OXAIPN is clinically challenging. Several objective and measurable early biomarkers for OXAIPN prediction have been described in recent years, becoming useful for informing clinical decisions about treatment. The purpose of this review is to critically review data on currently available or promising predictors of OXAIPN. Neurological monitoring, according to predictive factors for increased risk of OXAIPN, would allow clinicians to personalize treatment, by monitoring at-risk patients more closely and guide clinicians towards better counseling of patients about neurotoxicity effects of OXA.MDPI AG2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/179821Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/jpm11070669Journal of Personalized Medicine, 2021, vol. 11, num. 7, p. 669https://doi.org/10.3390/jpm11070669cc by (c) Velasco, Roser et al, 2021http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1798212026-05-27T06:46:51Z
dc.title.none.fl_str_mv Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
title Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
spellingShingle Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
Velasco, Roser
Marcadors bioquímics
Neurotoxicologia
Càncer gastrointestinal
Biochemical markers
Neurotoxicology
Gastrointestinal cancer
title_short Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
title_full Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
title_fullStr Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
title_full_unstemmed Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
title_sort Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
dc.creator.none.fl_str_mv Velasco, Roser
Alemany, Montse
Villagrán, Macarena
Argyriou, Andreas A.
author Velasco, Roser
author_facet Velasco, Roser
Alemany, Montse
Villagrán, Macarena
Argyriou, Andreas A.
author_role author
author2 Alemany, Montse
Villagrán, Macarena
Argyriou, Andreas A.
author2_role author
author
author
dc.subject.none.fl_str_mv Marcadors bioquímics
Neurotoxicologia
Càncer gastrointestinal
Biochemical markers
Neurotoxicology
Gastrointestinal cancer
topic Marcadors bioquímics
Neurotoxicologia
Càncer gastrointestinal
Biochemical markers
Neurotoxicology
Gastrointestinal cancer
description Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OXA infusion, and chronic non-length dependent sensory neuronopathy symmetrically affecting both upper and lower limbs in a stocking-and-glove distribution. No effective strategy has been established to reverse or treat OXAIPN. Thus, it is necessary to early predict the occurrence of OXAIPN during treatment and possibly modify the OXA-based regimen in patients at high risk as an early diagnosis and intervention may slow down neuropathy progression. However, identifying which patients are more likely to develop OXAIPN is clinically challenging. Several objective and measurable early biomarkers for OXAIPN prediction have been described in recent years, becoming useful for informing clinical decisions about treatment. The purpose of this review is to critically review data on currently available or promising predictors of OXAIPN. Neurological monitoring, according to predictive factors for increased risk of OXAIPN, would allow clinicians to personalize treatment, by monitoring at-risk patients more closely and guide clinicians towards better counseling of patients about neurotoxicity effects of OXA.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/179821
url https://hdl.handle.net/2445/179821
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/jpm11070669
Journal of Personalized Medicine, 2021, vol. 11, num. 7, p. 669
https://doi.org/10.3390/jpm11070669
dc.rights.none.fl_str_mv cc by (c) Velasco, Roser et al, 2021
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Velasco, Roser et al, 2021
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI AG
publisher.none.fl_str_mv MDPI AG
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406747533246464
score 15,300719

Similares en LA Referencia